Inhalation to be Used in New Trial

A new study, Dynavax DV9-NSC-01 NSCLC, is now open to enrollment at UCLA Main Campus. This is a phase Ib study of the investigational drug DV281, which is an immunotherapy, with the approved drug nivolumab, which is another type of immunotherapy. Interestingly, DV281 will be administered via inhalation with the intention of delivering the drug directly to the lungs, rather than more common methods like intravenous (IV) infusion or oral tablets. This study is for patients with advanced non-small cell lung cancer (NSCLC) who have had 1-2 prior lines of systemic therapy, which may include prior PD-1/PD-L1 inhibitor therapy. Enrolled subjects will receive treatment with both DV281 and nivolumab.

Solid Malignancy Tissue Bank Expanding to UCLA Satellite Sites

UCLA is excited to announce that Dr. Edward Garon’s Correlative Research Team will be expanding recruitment for its Solid Malignancy Tissue Bank to UCLA’s Satellite Sites. This will be a first step toward the upcoming expansion of the Tissue Bank to the TRIO-US Network. The Tissue Bank is a repository for tissue and bodily fluid specimens for use in future research to evaluate how cancer develops and how it responds to new therapies. Currently, the Bank allows for the collection of tissue from tumor biopsies (new biopsies are not performed spefically for the Tissue Bank), blood, saliva, urine, and stool for patients with solid malignancies who are receiving or may be eligible for targeted therapy or immunotherapy, or who may participate in clinical trials. Blood collection consists of no more than two blood draws, taken at least 6 weeks apart and at appointments during which blood draws are already occurring. By expanding enrollment for this Tissue Bank, UCLA will continue to grow its repository of tissue and bodily fluid specimens for future research projects. “We are extremely excited for the future research to come from this endeavor, and for the contributions it will make to the research goals of the program as a whole.” ~Dr. Edward Garon

Learn more